SEARCH

SEARCH BY CITATION

References

  • 1
    Krulich L, Dharwal APS, McCann SM. Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro. Endocrinology 1968; 83: 78390.
  • 2
    Brazeau P, Vale W, Burgus R, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Sci Wash DC 1973; 179: 779.
  • 3
    Harris AG. Somatostatin and somatostatin analogues pharmacokinetics and pharmacodynamic effects. Gut 1994; 35(Suppl. 3): S14.
  • 4
    Lamberts SWJ, Van Der Levy A-J, De Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996; 334: 24654.
  • 5
    Grossman I & Simon D. Potential gastrointestinal uses of somatostatin and its synthetic analogue octreotide. Am J Gastroenterol 1990; 85: 106172.
  • 6
    Fried M. Octreotide in the treatment of refractory diarrhea. Digestion 1999; 60(Suppl. 2): 426.
  • 7
    Farthing MJG. Octreotide in the treatment of refractory diarrhea and intestinal fistulas. Gut 1994; 35(Suppl. 3): S510.
  • 8
    Moertel CG, Johnson M, McKusick MA, et al. Ann Intern Med 1994; 120: 3029.
  • 9
    Shrier I. Stretching before exercise: an evidence-based approach [editorial]. Br J Sports Med 2000; 34: 3245.
  • 10
    Feinstein AR & Horwitz RI. Problems in the ‘evidence’ of ‘evidence-based medicine’. Am J Med 1998; 103: 52935.
  • 11
    Manfredi R, Vezzadini P, Fanti MP, Chiodo F. Vasoactive intestinal polypeptide (VIP) secretion and refractory diarrhea in patients with AIDS or AIDS-related complex (ARC). Scand J Infect Dis 1994; 26: 557.
  • 12
    Moroni M, Esposito R, Cernuschi M, Franzetti F, Carosi GP, Fiori GP. Treatment of AIDS-related refractory diarrhea with octreotide. Digestion 1993; 54(Suppl. 1): 302.
  • 13
    Liberti A, Bisogno A, Izzo E. Octreotide treatment in secretory and cryptosporidial diarrhea in patients with acquired immunodeficiency syndrome (AIDS): Clinical evaluation. J Chemother 1992; 4: 3035.
  • 14
    Fanning M, Monte M, Sutherland LR, Broadhead M, Murphy GF, Harris AG. Pilot study of sandostatin (octreotide) therapy of refractory HIV-associated diarrhea. Dig Dis Sci 1991; 36: 47680.
  • 15
    Cello JP, Grendell JH, Basuk P, et al. Effect of octreotide on refractory AIDS-associated diarrhea. Ann Intern Med 1991; 115: 70510.
  • 16
    Romeu J, Miro JM, Sirera G, et al. Efficacy of octreotide in the management of chronic diarrhea in AIDS. AIDS 1991; 5: 14959.
  • 17
    Montaner JSG & Harris AG and the Octreotide International Multicenter AIDS Diarrhea Study Group. Octreotide therapy in AIDS-related refractory diarrhea: Results of a multicenter Canadian–European study. AIDS 1995; 9: 20910.
  • 18
    Wasserman EI, Hidalgo M, Hornedo J, Cortés-Funes H. Octreotide (SMS 201-995) for hematopoietic support-dependent high-dose chemotherapy (HSD-HDC)-related diarrhea: Dose finding study and evaluation of efficacy. Bone Marrow Transplantation 1997; 20: 7114.
  • 19
    Meropol NJ, Blumenson LE, Creaven PJ. Octreotide does not prevent diarrhea in patients treated with weekly 5-fluorouracil plus high-dose leucovorin. Am J Clin Oncol 1998; 21: 1358.DOI: 10.1097/00000421-199804000-00007
  • 20
    Wadler S, Haynes H, Wiernik PH. Phase I trial of the somatostatin analog octreotide acetate in the treatment of fluoropyrimidine-induced diarrhea. J Clin Oncol 1995; 13: 2226.
  • 21
    Petrelli NJ, Rodriguez-Bigas M, Rustum Y, Herrera L, Creaven P. Bowel rest, intravenous hydration and continuous high-dose infusion of octreotide acetate for the treatment of chemotherapy-induced diarrhea in patients with colorectal carcinoma. Cancer 1993; 72: 15436.
  • 22
    Cascinu S, Fedeli A, Fedeli SL, Catalano G. Control of chemotherapy-induced diarrhea with octreotide in patients receiving 5-fluorouracil. Eur J Cancer 1992; 28: 4823.
  • 23
    Ippoliti C, Champlin R, Bugazia N, et al. Use of octreotide in the symptomatic management of diarrhea induced graft-versus-host disease in patients with hematologic malignancies. J Clin Oncol 1997; 15: 33504.
  • 24
    Crouch MA, Restino MS, Cruz JM, Perry JJ, Hurd DD. Octreotide acetate in refractory bone marrow transplant-associated diarrhea. Ann Pharmacother 1996; 30: 3316.
  • 25
    Ely P, Dunitz J, Rogosheske J, Weisdorf D. Use of somatostatin analogue, octreotide acetate, in the management of acute gastrointestinal graft-versus-host disease. Am J Med 1991; 90: 70710.
  • 26
    Mackie CR, Jenkins SA, Hartley MN. Treatment of severe post vagotomy/post gastrectomy symptoms with the somatostatin analogue octreotide. Br J Surg 1991; 78: 133843.
  • 27
    Nightingale JMD, Walker ER, Burnham WR, Farthing MJG, Lennard-Jones JE. Octreotide (a little somatostatin analogue) improves the quality of life in some patients with a short intestine. Aliment Pharmacol Ther 1989; 3: 36773.
  • 28
    O'Keefe SJD, Peterson ME, Flemming CR. Octreotide as an adjunct to home parenteral nutrition in the management of permanent end-jejunostomy syndrome. J Parenter Enteral Nutr 1994; 18: 2636.
  • 29
    Beaugerie L, Baumer PH, Chaussade S, et al. Treatment of refractory diarrhea in AIDS with acetorphan and octreotide: a randomized cross over study. Eur J Gastroenterol 1996; 8: 4859.
  • 30
    Compean DG, Jimenez JR, De La Garza FG, et al. Octreotide therapy of large-volume refractory AIDS-associated diarrhea: a randomized controlled trial. AIDS 1994; 8: 15637.
  • 31
    Simon DM, Cello JP, Valenzuela J, et al. Multicenter trial of octreotide in patients with refractory acquired immunodeficiency syndrome-associated diarrhea. Gastroenterology 1995; 108: 175360.
  • 32
    Cascinu S, Fedeli A, Fedeli SL, Catalano G. Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial. J Clin Oncol 1993; 11: 14851.
  • 33
    Gebbla V, Carrera I, Testa A, et al. Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy. Anti-Cancer Drugs 1993; 4: 4435.
  • 34
    Cascinu S, Fedeli A, Fedeli SL, Catalano G. Control of chemotherapy-induced diarrhea with octreotide. Oncology 1994; 51: 703.
  • 35
    Geller RB, Gilmore CE, Dix SP, et al. Randomized trial of loperamide versus dose escalation of octreotide acetate for chemotherapy-induced diarrhea in bone marrow transplant and leukemia patients. Am J Hematol 1995; 50: 16772.
  • 36
    Abbas Z, Moid I, Khan AH, et al. Efficacy of octreotide in diarrhea due to vibrio cholerae: a randomized, controlled trial. Ann Trop Med Parasite 1996; 90: 50713.
  • 37
    Molla AM, Gyr K, Bardhan PK, Molla A. Effect of intravenous somatostatin on stool output in diarrhea due to vibrio cholerae. Gastroenterology 1984; 87: 8457.
  • 38
    Geer RJ, Richards WO, O'Dorisio TM, et al. Efficacy of octreotide acetate in treatment of severe post gastrectomy dumping syndrome. Ann Surg 1990; 212: 67887.
  • 39
    Ladefoged K, Christensen KC, Hegnhoj J, Jarnum S. Effect of a long acting somatostatin analogue SMS 201-995 on jejunostomy effluents in patients with severe short bowel syndrome. Gut 1989; 30: 9439.
  • 40
    Cooper JC, Williams NS, King RFGJ, Barker MCJ. Effects of a long-acting somatostatin analogue in patients with severe ileostomy diarrhea. Br J Surg 1986; 73: 12831.
  • 41
    Dharmasathaporn K, Sherwin RS, Cataland S, Jafe B, Dobbins J. Somatostatin inhibits diarrhea in the carcinoid syndrome. Ann Intern Med 1980; 92: 689.
  • 42
    Kvols LK, Moertel CG, O'Connell MJ, Schutt AJ, Rubin J, Hahn RG. Treatment of the malignant carcinoid syndrome: Evaluation of a long-acting somatostatin analogue. N Engl J Med 1986; 315: 6636.
  • 43
    Davis GR, Camp RC, Raskin P, Krejs GJ. Effect of somatostatin infusion on jejunal water and electrolyte transport in a patient with secretory diarrhea due to malignant carcinoid syndrome. Gastroenterology 1980; 78: 3469.
  • 44
    Vinik ANI, Tsai ST, Moattari AR, Cheung P, Eckhauser FE, Cho Y. Somatostatin analogue (SMS 201-995) in the management of gastroenteropancreatic tumors and diarrhea syndromes. Am J Med 1986; 81(Suppl. 6B): 2340.
  • 45
    Dharmasathaporn K, Racusen L, Dobbins JW. Effect of somatostatin on ion transport in the rat colon. J Clin Invest 1980; 66: 81320.
  • 46
    Dharmasathaporn K, Sherwin RS, Dobbins JW. Somatostatin inhibits fluid secretion in the rat jejunum. Gastroenterology 1980; 8: 15548.
  • 47
    Dharmasathaporn K, Binder HJ, Dobbins JW, Zeo L. Somatostatin stimulates sodium and chloride absorption in the rat ileum. Gastroenterology 1980; 78: 155965.
  • 48
    Roberts WG, Fedorak RN, Chang EB. In vitro effects of the long-acting somatostatin analogue SMS 201-995 on electrolyte transport by the rabbit ileum. Gastroenterology; 1988; 94: 134350.
  • 49
    Dueno MI, Bai JC, Santangelo WC, Krejs GJ. Effect of somatostatin analog on water and electrolyte transport and transit time in human small bowel. Dig Dis Sci 1987; 32: 10926.
  • 50
    Fassler JE, O'Dorisio TM, Goddard CG, Gagnella TS. Peptides of human immunodeficiency virus (HIV) evoke rat colonic electrolyte secretion inhibitable by the somatostatin analog octreotide. Life Sci 1991; 48: PL1317.
  • 51
    Robinson EN Jr & Fogel R. SMS 201-995, a somatostatin analogue, and diarrhea in the acquired immunodeficiency syndrome AIDS. Ann Intern Med 1988; 108: 6801.
  • 52
    Dharmsathaporn K, Gorelick FS, Sherwin RS, Cataland S, Dobbins JW. Somatostatin decreases diarrhea in patients with the short-bowel syndrome. J Clin Gastroenterol 1982; 4: 5214.
  • 53
    Dudl RJ, Anderson DS, Forsythe AB, Ziegler MG, O'Dorisio TM. Treatment of diabetic diarrhea and orthostatic hypotension with somatostatin analogue SMS 201-995. Am J Med 1987; 83: 5848.
  • 54
    Mourad FH, Gorard D, Thillainayagam AV, Colin-Jones D, Farthing MJG. Effective treatment of diabetic diarrhea with somatostatin analogue, octreotide. Gut 1992; 33: 157880.
  • 55
    Escorsell A, Bandi JC, Andreu V, et al. Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension. Gastroenterology 2001; 120: 1619.
  • 56
    Londong W, Agerer M, Kutz K, Landgraf R, Londong V. Diminishing efficacy of octreotide (SMS 201-995) on gastric functions of healthy subjects during one-week administration. Gastroenterology 1989; 96: 71322.
  • 57
    Nehra V, Camilleri M, Burton D, Oenning LV, Kelly DG. An open trial of octreotide long-acting release in the management of short bowel syndrome. Am J Gastroenterol 2001; 96: 14948.
    Direct Link:
  • 58
    Harris AG, O'Dorisio TM, Woltering LB, et al. Consensus statement: Octreotide dose titration in secretory diarrhea. Dig Dis Sci 1995; 40: 146473.